Applied Therapeutics (APLT) EBIT (2023 - 2025)
Historic EBIT for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to -$16.8 million.
- Applied Therapeutics' EBIT rose 4365.73% to -$16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$98.4 million, marking a year-over-year decrease of 663.06%. This contributed to the annual value of -$104.3 million for FY2024, which is 6161.62% down from last year.
- According to the latest figures from Q3 2025, Applied Therapeutics' EBIT is -$16.8 million, which was up 4365.73% from -$23.1 million recorded in Q2 2025.
- In the past 5 years, Applied Therapeutics' EBIT ranged from a high of -$10.9 million in Q1 2023 and a low of -$33.0 million during Q4 2024
- Moreover, its 3-year median value for EBIT was -$21.0 million (2023), whereas its average is -$21.3 million.
- In the last 5 years, Applied Therapeutics' EBIT plummeted by 9426.23% in 2024 and then soared by 4365.73% in 2025.
- Over the past 3 years, Applied Therapeutics' EBIT (Quarter) stood at -$21.0 million in 2023, then crashed by 57.19% to -$33.0 million in 2024, then skyrocketed by 49.25% to -$16.8 million in 2025.
- Its last three reported values are -$16.8 million in Q3 2025, -$23.1 million for Q2 2025, and -$25.5 million during Q1 2025.